SecBot SecBot
8-K ·Filed Sep 15, 2026

SMMT

Summit Therapeutics Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001599298-26-000081
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The consistent OS data across geographies and the positive head-to-head HARMONi-2 data against Keytruda significantly de-risk the ivonescimab program ahead of the November PDUFA. Traders should watch for potential pre-approval investor events and any FDA advisory committee briefing documents. The stock is likely to re-rate higher as the probability of approval and peak sales estimates increase.

DirectionBullish
Confidencehigh
Horizonweeks

ivonescimab

◆ Mixed Named in this 8-K
Impact
Phase
Filed/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
Time to market
If approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
Next catalyst
None dated

What to watchThe November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$17.40
T+0 close · Sep 15, 2026 · via day close
Latest settled
−10.80%
T+20 · $15.52 · next T+60 in 22d
Vs SPY
−13.78%
α at T+20
Latest observation
−11.17%
T+43 · FF3 residual α
  1. T+0 · Sep 15 $17.40entry
  2. T+1 · 2mo ago +0.80%α +0.48% · $17.54
  3. T+5 · 8w ago +2.59%α +1.77% · $17.85
  4. T+20 · 5w ago −10.80%α −13.78% · $15.52
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Summit Therapeutics presented updated overall survival (OS) data from the global Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutated NSCLC) and detailed OS results from the China-based HARMONi-2 trial (ivonescimab monotherapy vs. pembrolizumab) at WCLC 2026. The HARMONi data showed a consistent OS benefit with a hazard ratio of 0.76 (nominal p=0.0151) in the global ITT population, with western patients now showing a similar HR of 0.76, reinforcing the drug's profile ahead of the November 14, 2026 PDUFA date. HARMONi-2 showed a statistically significant OS benefit for ivonescimab over pembrolizumab (HR 0.73, p=0.009), further strengthening the clinical case for the asset across multiple lung cancer settings.

Key Facts

  • Updated HARMONi OS HR of 0.76 (95% CI: 0.61-0.95; nominal p=0.0151) in global ITT population at June 2026 data cut-off.
  • Western patient subgroup OS HR improved to 0.76 (95% CI: 0.52-1.10) with longer follow-up (median 23.2 months), matching the global trend.
  • HARMONi-2 showed ivonescimab monotherapy beat pembrolizumab on OS with HR 0.73 (95% CI: 0.57-0.95; p=0.009), including a 7.6-month median OS advantage (30.8 vs 22.6 months).
  • PDUFA goal date for the ivonescimab BLA in the U.S. is November 14, 2026.
  • No new safety signals were observed in either HARMONi or HARMONi-2 with longer follow-up.

Financial Impact

Positive catalyst for SMMT stock; ivonescimab is the sole pipeline asset. Approval in EGFR-mutated NSCLC (HARMONi) represents a multi-billion-dollar peak sales opportunity. HARMONi-2 data supports potential label expansion into first-line PD-L1 positive NSCLC, significantly increasing the addressable market.

revenuemarket_cap

Risk Factors

  • The HARMONi OS benefit did not reach statistical significance at the primary analysis (p=0.057), and the updated analysis uses a nominal p-value, which may be a point of FDA scrutiny.
  • HARMONi-2 is a single-region China study; the FDA may require a global confirmatory trial for a first-line indication.
  • Competition from other bispecific antibodies and antibody-drug conjugates in the NSCLC space is intense.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001599298-26-000081
Document: a2026_prx0915xharmoniltf.htm0001599298-26-000081
Document: 0001599298-26-000081-index-headers.html0001599298-26-000081
Document: 0001599298-26-000081-index.html0001599298-26-000081
Document: 0001599298-26-000081.txt0001599298-26-000081

Track record

23 reports on SMMT

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bearish 7/10 Entry $11.43 Now $11.82 −3.41% settles Nov 17
  2. Nov 4, 202612d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
  4. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $11.82 −26.90% ▼ −12.24% −7.84% vs SPY
  5. Oct 21, 202626d ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $11.82 −25.33% ▼ −1.77% −0.59% vs SPY
  6. Oct 19, 202628d ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $11.82 −24.08% ▲ +3.34% +3.00% vs SPY
  7. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $11.82 −27.88% ▲ +3.17% +3.38% vs SPY
  8. Sep 15, 20268w ago 8-K Bullish 7/10 Viewing Entry $17.40 to $17.54 Now $11.82 −32.07% ▲ +0.80% +0.48% vs SPY
  9. Sep 14, 20269w ago 8-K Bullish 7/10 Entry $18.42 to $17.40 Now $11.82 −35.83% ▼ −5.54% −5.08% vs SPY
  10. Sep 3, 202610w ago 8-K Bullish 6/10 Entry $17.13 to $17.61 Now $11.82 −31.00% ▲ +2.77% +3.16% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 8h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026